Clesrovimab is an extended half-life RSV neutralizing antibody in development for all infants in their first RSV season and ...

There has been a surge in cases of a deadly virus with more babies admitted to hospital, according to the UK Health Security ...

The drug clesrovimab also helped reduce RSV associated hospitalizations by 84.2% compared to placebo, Merck said.

Doctors have issued a warning to parents over a common bug which can cause dangerous lung infections - with babies and young ...

As a mother, I understand all too well the stress that comes when our little ones are sick, especially during RSV season.

Merck reported positive results for its experimental treatment designed to protect infants from RSV. The mid to late-stage ...

A large new study says the RSV vaccine is 80% effective at preventing hospitalization in older adults due to complications from the illness, and works just as well at protecting them from death or ...